Skip to main content
Fig. 5 | Acta Neuropathologica Communications

Fig. 5

From: Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer’s Disease

Fig. 5

Neurochemical abnormalities occurring in the retinas from Tg2576 AD mice are responsive to treatment with 12A12mAb. Representative images of Western blotting analyses (a) carried out on equal amounts of total protein extract (50 µg) from retinas of animals of three experimental groups (wild-type, Tg2576 and Tg2576 + mAb). Filters were probed with antibodies against the Choline acetyltransferase (ChAT), the muscarinic acetylcholine receptor (M1), the vesicular GLUtamate transporter1 (vGLUT1), the vesicular GABA transporter (vGAT). Data were quantified for molecular weight size ranges for each antibody and normalized to β-actin which was used as loading control. Relative intensity of each protein was calculated and semi-quantitative densitometric analysis (n = 6) is shown (b). Arrows on the right side indicate the molecular weight (kDa) of bands calculated from migration of standard proteins. Statistically significant differences were calculated by one-way analysis of variance (ANOVA) followed by Bonferroni’s post-hoc test for multiple comparison among more than two groups. p < 0.05 was accepted as statistically significant (*p < 0.05; **p < 0.01; ***p < 0.0005; ****p < 0.0001)

Back to article page